· Pharma · Pharma Desk
Novo's higher-dose Wegovy posted up to 28% mean weight loss in AMAZE-2, while Dr. Reddy's became the first generic semaglutide on Canadian shelves on May 16-20. Lilly raised 2026 guidance to $82–$85B on tirzepatide strength, Amazon expanded same-day Ozempic dispensing, and Vincentage's oral VCT220 cleared a Chinese Phase 3 at 12.4%.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.